Funding
Initiatives that further the goal of HIV vaccine discovery are highlighted below.
Featured Initiatives
| New Funding Opportunities |
|
B Cell Immunology Partnership Program For HIV-1 Vaccine Discovery will fund multidisciplinary research teams to conduct fundamental research that will inform HIV immunization strategies to elicit broadly neutralizing HIV antibodies. This program will foster networking and sharing of knowledge, reagents and protocols to enhance vaccine discovery. December 4, 2009 is the deadline for receiving applications.
Dissecting the Early HIV Immune Response: A Systems Biology Approach will fund multidisciplinary teams to use systems biology approaches to develop a comprehensive understanding of innate and early adaptive immune responses that contribute to protection from HIV/SIV exposure or infection, or facilitate viral acquisition. Knowledge gained from these research efforts should ultimately seek to provide a foundation for the development of novel therapeutic or vaccine approaches against HIV-1. The application due date is December 1, 2009.
In May 2009, NIAID's AIDS Research Advisory Committee (ARAC) approved a new concept for initiative development titled "Mechanisms and Prevention of Sexual Transmission of HIV/SIV."
Note: Concepts represent early planning stages for PAs, RFAs or RFPs and are reviewed by NIAID's AIDS Research Advisory Committee (ARAC) for their input and approval. ARAC approval does not guarantee that a concept will become an initiative, and concepts are intended only to inform the research community about potential initiatives. |
Ongoing Programs
Phased Innovation Awards (PIA) fund exploratory projects to develop novel and innovative concepts that exhibit the potential to advance preventive HIV vaccine design or evaluation.
HIV Vaccine Research and Design (HIVRAD) program advances concepts further towards the development of a preventive AIDS vaccine.
Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) supports the later stages of preventive HIV/AIDS vaccine concept refinement and testing, culminating in human studies.
HIV Vaccine Design and Development Teams (HVDDT) fund consortia of scientists with development experience from industry and/or academia that have identified a promising vaccine concept and envisioned a product worthy of targeted development.
Highly Innovative Tactics to Interrupt Transmission of HIV (HIT-IT) funds research on novel, unconventional, outside-the-box, high-risk, and/or potential high-impact approaches that may provide long-term, safe protection from HIV infection.
Basic HIV Vaccine Discovery Research funds research in basic disciplines including immunology, virology, cellular and structural biology, and host genetics that can potentially lead to new discoveries and concepts, approaches and strategies applicable to design of an optimal preventive HIV vaccine.
back to top